| Metabolic reprogramming in cancer cells: emerging molecular mechanisms and novel therapeutic approaches C Navarro, Á Ortega, R Santeliz, B Garrido, M Chacín, N Galban, I Vera, ... Pharmaceutics 14 (6), 1303, 2022 | 82 | 2022 |
| Role of Endocrine-Disrupting Chemicals in the Pathogenesis of Non-Alcoholic Fatty Liver Disease: A Comprehensive Review R Cano, J Perez, L Angarita Dávila, A Ortega, Y Gómez, ... International Journal of Molecular Sciences 22 (9), 4807, 2021 | 81 | 2021 |
| Depression as a neuroendocrine disorder: emerging neuropsychopharmacological approaches beyond monoamines M Chávez-Castillo, V Núñez, M Nava, Á Ortega, M Rojas, V Bermúdez, ... Advances in Pharmacological and Pharmaceutical Sciences 2019 (1), 7943481, 2019 | 78 | 2019 |
| Alzheimer’s disease and type 2 diabetes mellitus: Pathophysiologic and pharmacotherapeutics links M Rojas, M Chávez-Castillo, J Bautista, Á Ortega, M Nava, J Salazar, ... World Journal of Diabetes 12 (6), 745, 2021 | 61 | 2021 |
| Advanced glycation end products: new clinical and molecular perspectives J Salazar, C Navarro, Á Ortega, M Nava, D Morillo, W Torres, ... International journal of environmental research and public health 18 (14), 7236, 2021 | 54 | 2021 |
| The YAP/TAZ signaling pathway in the tumor microenvironment and carcinogenesis: Current knowledge and therapeutic promises Á Ortega, I Vera, MP Diaz, C Navarro, M Rojas, W Torres, H Parra, ... International Journal of Molecular Sciences 23 (1), 430, 2021 | 50 | 2021 |
| Specialized pro-resolving lipid mediators: the future of chronic pain therapy? M Chávez-Castillo, Á Ortega, L Cudris-Torres, P Duran, M Rojas, ... International journal of molecular sciences 22 (19), 10370, 2021 | 35 | 2021 |
| Electroconvulsive therapy in psychiatric disorders: a narrative review exploring neuroendocrine–immune therapeutic mechanisms and clinical implications M Rojas, D Ariza, Á Ortega, ME Riaño-Garzón, M Chávez-Castillo, ... International Journal of Molecular Sciences 23 (13), 6918, 2022 | 26 | 2022 |
| Metabolic risk in depression and treatment with selective serotonin reuptake inhibitors: are the metabolic syndrome and an increase in cardiovascular risk unavoidable? M Chávez-Castillo, Á Ortega, M Nava, J Fuenmayor, V Lameda, ... Vessel Plus 2, N/A-N/A, 2018 | 24 | 2018 |
| Lipid accumulation product is more related to insulin resistance than the visceral adiposity index in the Maracaibo City Population, Venezuela V Bermúdez, J Salazar, J Fuenmayor, M Nava, Á Ortega, P Duran, ... Journal of obesity 2021 (1), 5514901, 2021 | 18 | 2021 |
| Is “leptin resistance” another key resistance to manage type 2 diabetes? J Salazar, M Chávez-Castillo, J Rojas, A Ortega, M Nava, J Pérez, ... Current diabetes reviews 16 (7), 733-749, 2020 | 18 | 2020 |
| Psycho-neuro-endocrine-immunological basis of the placebo effect: potential applications beyond pain therapy Á Ortega, J Salazar, N Galban, M Rojas, D Ariza, M Chávez-Castillo, ... International journal of molecular sciences 23 (8), 4196, 2022 | 14 | 2022 |
| SGLT2i and GLP‐1RA in Cardiometabolic and Renal Diseases: From Glycemic Control to Adipose Tissue Inflammation and Senescence L D′ Marco, V Morillo, JL Gorriz, MK Suarez, M Nava, Á Ortega, H Parra, ... Journal of Diabetes Research 2021 (1), 9032378, 2021 | 13 | 2021 |
| Depression as an immunometabolic disorder: exploring shared pharmacotherapeutics with cardiovascular disease M Chávez-Castillo, M Nava, Á Ortega, M Rojas, V Núñez, J Salazar, ... Current neuropharmacology 18 (11), 1138-1153, 2020 | 13 | 2020 |
| Phytotherapy for cardiovascular disease: a bench-to-bedside approach M Chávez-Castillo, Á Ortega, P Duran, D Pirela, M Marquina, C Cano, ... Current Pharmaceutical Design 26 (35), 4410-4429, 2020 | 10 | 2020 |
| Prevalence and Risk Factors associated with Impaired Fasting Glucose in Adults from Maracaibo City, Venezuela V Bermudez, J Salazar, R Gonzalez, A Ortega, M Calvo, LC Olivar, ... J Diabetes Metab 7 (683), 2, 2016 | 10 | 2016 |
| Psychosis in Parkinson’s disease: looking beyond dopaminergic treatments M Rojas, M Chávez-Castillo, P Duran, Á Ortega, MJ Bautista-Sandoval, ... Current Pharmaceutical Design 28 (33), 2725-2741, 2022 | 9 | 2022 |
| Retinoblastoma: un enfoque molecular, clínico y terapéutico J Rojas, C Cano, E Machín, V Bermúdez, C Garicano, Á Ortega, M Rojas, ... Archivos venezolanos de farmacología y terapéutica 36 (5), 115-131, 2017 | 8 | 2017 |
| Exploring Phytotherapeutic Alternatives for Obesity, Insulin Resistance and Diabetes Mellitus M Chávez-Castillo, V Nuñez, M Rojas, Á Ortega, P Durán, D Pirela, ... Current pharmaceutical design, 2020 | 5 | 2020 |
| Non-HDL cholesterol is better than LDL-c at predicting atherosclerotic cardiovascular disease risk factors clustering, even in subjects with near-to-normal triglycerides: A … V Bermúdez, W Torres, J Salazar, MS Martínez, E Rojas, LC Olivar, ... F1000Research 7 (504), 504, 2019 | 5 | 2019 |
Valmore BermudezUniversidad Simón Bolívar, ColombiaVerificeret mail på unisimonbolivar.edu.co